{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:26:15Z","timestamp":1794565575402,"version":"4.9.1"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-23-00885"],"award-info":[{"award-number":["25-23-00885"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.119026","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:56:57Z","timestamp":1780300617000},"page":"119026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evolution of PSMA-GRPr heterobivalent radiolabeled conjugates for the diagnosis and therapy of prostate cancer"],"prefix":"10.1016","volume":"316","author":[{"given":"Gleb P.","family":"Grigoriev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K.","family":"Beloglazkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-6100","authenticated-orcid":false,"given":"Stanislav A.","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119026_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119026_bib2","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119026_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0090-4295(97)00177-5","article-title":"Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase","volume":"49","author":"Heston","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.ejmech.2026.119026_bib4","first-page":"679","article-title":"Small-molecule PSMA ligands","volume":"24","author":"Machulkin","year":"2016","journal-title":"Cur. State, SAR Perspect."},{"key":"10.1016\/j.ejmech.2026.119026_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119026_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-Radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119026_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40291-023-00665-y","article-title":"Flotufolastat F 18: diagnostic first approval","volume":"27","author":"Heo","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ejmech.2026.119026_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14737140.2022.2081155","article-title":"Piflufolastat F-18 ( 18 F-DCFPyL) for PSMA PET imaging in prostate cancer","volume":"22","author":"Voter","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.119026_bib11","doi-asserted-by":"crossref","first-page":"11215","DOI":"10.1016\/S0021-9258(18)60946-9","article-title":"Identification of the bombesin receptor on murine and human cells by cross-linking experiments","volume":"262","author":"Kris","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib12","first-page":"1139","article-title":"Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-TYR6, \u03b2-ALA11, PHE13, NLE14] bombesin(6-14)","volume":"8","author":"Reubi","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119026_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbcan.2006.01.003","article-title":"Gastrin-releasing peptide and cancer","volume":"1766","author":"Patel","year":"2006","journal-title":"Biochim. Biophys. Acta, Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119026_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","article-title":"Prostate cancer theranostics targeting gastrin-releasing peptide receptors","volume":"20","author":"Baratto","year":"2018","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2026.119026_bib15","first-page":"88","article-title":"Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts","volume":"48","author":"De Visser","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119026_bib16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.2042-7158.1970.tb08465.x","article-title":"Some pharmacological actions of alytesin and bombesin","volume":"22","author":"Erspamer","year":"1970","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119026_bib17","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1073\/pnas.2216230120","article-title":"Structures of human gastrin-releasing peptide receptors bound to antagonist and agonist for cancer and itch therapy","volume":"120","author":"Peng","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119026_bib18","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s002590000355","article-title":"Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study","volume":"27","author":"Van de Wiele","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119026_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00259-019-04503-4","article-title":"Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements","volume":"47","author":"Baratto","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119026_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ph16050674","article-title":"Peptide radioligands in cancer theranostics: agonists and antagonists","volume":"16","author":"Nock","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119026_bib20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2967\/jnumed.107.045054","article-title":"Bombesin receptor antagonists may be preferable to agonists for tumor targeting","volume":"49","author":"Cescato","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119026_bib21","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-08-3145","article-title":"Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic acid\u2013conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides","volume":"15","author":"Mansi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119026_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113752","article-title":"PSMA-targeted low-molecular double conjugates for diagnostics and therapy","volume":"225","author":"Petrov","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib24","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/bph.12106","article-title":"Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands","volume":"168","author":"Vauquelin","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119026_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00259-010-1615-x","article-title":"PET imaging of \u03b1v\u03b23 integrin expression in tumours with 68Ga-labelled mono-, di- and tetrameric RGD peptides","volume":"38","author":"Dijkgraaf","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119026_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ph13080173","article-title":"Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy","volume":"13","author":"Judmann","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119026_bib27","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bc1004284","article-title":"Cell-specific targeting by heterobivalent ligands","volume":"22","author":"Josan","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib28","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0960-894X(01)00294-3","article-title":"Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase","volume":"11","author":"Savini","year":"2001","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119026_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2967\/jnumed.107.048009","article-title":"18 F-Labeled BBN-RGD heterodimer for prostate cancer imaging","volume":"49","author":"Li","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119026_bib30","series-title":"Heterobivalent Imaging Agents for Simultaneous Targeting Prostate-specific Membrane Antigen (PSMA) and Hepsin","author":"Byun","year":"2011"},{"key":"10.1016\/j.ejmech.2026.119026_bib31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3390\/cancers11091371","article-title":"Bispecific GRPR-antagonistic Anti-PSMA\/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer","volume":"11","author":"Mitran","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119026_bib32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/pharmaceutics11070358","article-title":"Synthesis and preclinical evaluation of radio-iodinated GRPR\/PSMA bispecific heterodimers for the theranostics application in prostate cancer","volume":"11","author":"Abouzayed","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119026_bib33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MNM.0000000000000966","article-title":"Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer","volume":"40","author":"Escudero-Castellanos","year":"2019","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ejmech.2026.119026_bib34","first-page":"11","volume":"5","author":"Bandari","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119026_bib35","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10967-018-6285-3","article-title":"Preparation and preclinical evaluation of 68Ga-iPSMA-BN as a potential heterodimeric radiotracer for PET-imaging of prostate cancer","volume":"318","author":"Mendoza-Figueroa","year":"2018","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/acs.bioconjchem.5b00687","article-title":"Novel bispecific PSMA\/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer","volume":"27","author":"Liolios","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pros.22784","article-title":"Preclinical evaluation of a bispecific low\u2010molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer","volume":"74","author":"Eder","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2026.119026_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.nucmedbio.2014.01.001","article-title":"Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr\/PSMA) of prostate cancer","volume":"41","author":"Bandari","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119026_bib39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acs.bioconjchem.5c00033","article-title":"Choice of an optimal modular strategy for the synthesis of DOTA-containing heterobivalent agents targeting PSMA and GRPr","volume":"36","author":"Petrov","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib40","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1021\/acsmedchemlett.4c00324","article-title":"Synthesis and preclinical evaluation of a bispecific PSMA-617\/RM2 heterodimer targeting prostate cancer","volume":"15","author":"Liolios","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119026_bib41","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/pharmaceutics16111358","article-title":"Theranostic potential of the iPSMA-Bombesin radioligand in patients with metastatic prostate cancer: a pilot study","volume":"16","author":"Gonz\u00e1lez-Rueda","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119026_bib42","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/acsmedchemlett.3c00057","article-title":"Modular one-pot strategy for the synthesis of heterobivalent tracers","volume":"14","author":"Bailly","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119026_bib43","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/cancers15020442","article-title":"Preclinical characterisation of PSMA\/GRPR-Targeting heterodimer [68Ga]Ga-BQ7812 for PET diagnostic imaging of prostate cancer: a step towards clinical translation","volume":"15","author":"Lundmark","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119026_bib44","series-title":"Synthesis and Characterization of a GRPR and PSMA Targeting Heterodimer for Theranostic Applications in Prostate Cancer","author":"Markink","year":"2023"},{"key":"10.1016\/j.ejmech.2026.119026_bib45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/MNM.0000000000001520","article-title":"Radiosynthesis and biological evaluation of 18F-labeled bispecific heterodimer targeted dual gastrin-releasing peptide receptor and prostate-specific membrane antigen for prostate cancer imaging","volume":"43","author":"Ye","year":"2022","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ejmech.2026.119026_bib46","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/acs.jmedchem.0c01785","article-title":"Development of heterobivalent Theranostic probes having high affinity\/selectivity for the GRPR\/PSMA","volume":"64","author":"Bandari","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.nucmedbio.2021.03.005","article-title":"[68Ga]Ga-iPSMA-Lys3-Bombesin: biokinetics, dosimetry and first patient PET\/CT imaging","volume":"96\u201397","author":"Rivera-Bravo","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119026_bib48","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/pharmaceutics12070614","article-title":"Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer\u2014optimization of the affinity towards PSMA by linker modification in murine model","volume":"12","author":"Lundmark","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119026_bib49","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s00259-024-06965-7","article-title":"Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA\/FAP heterobivalent tracer","volume":"52","author":"Wang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119026_bib50","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1021\/acs.molpharmaceut.2c01000","article-title":"Preclinical evaluation of a fibroblast activation protein and a prostate-specific membrane antigen dual-targeted probe for noninvasive prostate cancer imaging","volume":"20","author":"Wang","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119026_bib51","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1007\/s00259-022-05933-3","article-title":"Hetero-bivalent agents targeting FAP and PSMA","volume":"49","author":"Boinapally","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119026_bib52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/ph15030383","article-title":"Radiosynthesis and preclinical evaluation of bispecific PSMA\/FAP heterodimers for tumor imaging","volume":"15","author":"Hu","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119026_bib53","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/molecules28031088","article-title":"Synthesis and preclinical evaluation of three novel 68Ga-Labeled bispecific PSMA\/FAP-Targeting tracers for prostate cancer imaging","volume":"28","author":"Verena","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119026_bib54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/bc4005377","article-title":"Heterobivalent agents targeting PSMA and Integrin-\u03b1 v \u03b2 3","volume":"25","author":"Shallal","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib55","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s10967-017-5555-9","article-title":"Preparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical","volume":"314","author":"Escudero-Castellanos","year":"2017","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117050","article-title":"A novel androgen-independent radiotracer with dual targeting of NTSR1 and PSMA for PET\/CT imaging of prostate cancer","volume":"282","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib57","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1021\/acs.bioconjchem.9b00252","article-title":"Development of bispecific NT-PSMA heterodimer for prostate cancer imaging: a potential approach to address tumor heterogeneity","volume":"30","author":"Ma","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib58","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1039\/D4MD00491D","article-title":"Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics","volume":"15","author":"Previti","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316553","article-title":"225Ac-iPSMA-RGD for alpha-therapy dual targeting of stromal\/tumor cell PSMA and integrins","volume":"24","author":"Ocampo-Garc\u00eda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119026_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1659095","article-title":"A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR","volume":"8","author":"Arndt","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejmech.2026.119026_bib61","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejmech.2016.04.033","article-title":"Design, synthesis and biological evaluation of PSMA\/hepsin-targeted heterobivalent ligands","volume":"118","author":"Subedi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib62","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.7150\/thno.118972","article-title":"Optimizing PSMA-617-based inhibitors through charged linker modifications: insights into structure-activity relationships","volume":"16","author":"Geis","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119026_bib63","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/jlcr.3749","article-title":"Bispecific radioligands targeting prostate\u2010specific membrane antigen and gastrin\u2010releasing peptide receptors on the surface of prostate cancer cells","volume":"62","author":"Liolios","year":"2019","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2026.119026_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500128","article-title":"Two targets, one mission: heterobivalent metal\u2010based radiopharmaceuticals for prostate cancer imaging and therapy","volume":"20","author":"Sobral","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119026_bib65","doi-asserted-by":"crossref","first-page":"21644","DOI":"10.1021\/acs.jmedchem.4c01608","article-title":"Current status and perspectives of novel radiopharmaceuticals with heterologous dual-targeted functions: 2013\u20132023","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","article-title":"Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours","volume":"38","author":"Mansi","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119026_bib67","doi-asserted-by":"crossref","first-page":"36652","DOI":"10.1074\/jbc.M104566200","article-title":"Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor","volume":"276","author":"Tokita","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib68","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2967\/jnumed.111.094375","article-title":"Bombesin antagonist\u2013based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor\u2013positive tumors","volume":"52","author":"Abiraj","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119026_bib69","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acs.chemrev.8b00294","article-title":"Radioactive main group and rare Earth metals for imaging and therapy","volume":"119","author":"Kostelnik","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119026_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2025.2850","article-title":"Real-world application of cytalux for targeted imaging of occult peritoneal disease in epithelial ovarian cancer","volume":"22","author":"Baron","year":"2025","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119026_bib71","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: Enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119026_bib72","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: Brentuximab vedotin in first-line treatment of peripheral T-Cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119026_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213789","article-title":"Synthesis of radioiodinated compounds. Classical approaches and achievements of recent years","volume":"23","author":"Petrov","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119026_bib74","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1021\/acs.chemrev.8b00281","article-title":"Radioactive transition metals for imaging and therapy","volume":"119","author":"Boros","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119026_bib75","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm000406m","article-title":"Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)","volume":"44","author":"Kozikowski","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib76","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2174\/092986712799462667","article-title":"Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme","volume":"19","author":"Pavlicek","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib78","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1021\/acsomega.4c10142","article-title":"Structure\u2013activity relationships and biological insights into PSMA-617 and its derivatives with modified lipophilic linker regions","volume":"10","author":"Sch\u00e4fer","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119026_bib77","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1021\/acs.jcim.2c01269","article-title":"Combination of in silico and in vitro screening to identify novel glutamate carboxypeptidase II inhibitors","volume":"63","author":"Temml","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119026_bib79","series-title":"Radiopharm. Chem.","first-page":"335","article-title":"The radiopharmaceutical chemistry of the radioisotopes of copper","author":"Ling","year":"2019"},{"key":"10.1016\/j.ejmech.2026.119026_bib80","first-page":"242436","article-title":"Synthesis of a modified SiFA-PSMA inhibitor and its in vitro and in vivo analysis","volume":"65","author":"Gower-Fry","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119026_bib81","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/ph14050385","article-title":"Standardization of the [68Ga]Ga-PSMA-11 radiolabeling protocol in an automatic synthesis module: assessments for PET imaging of prostate cancer","volume":"14","author":"Fuscaldi","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119026_bib82","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Bene\u0161ov\u00e1","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib83","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acs.bioconjchem.7b00458","article-title":"Improving the imaging contrast of 68 Ga-PSMA-11 by targeted linker design: charged spacer moieties enhance the pharmacokinetic properties","volume":"28","author":"Baranski","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119026_bib84","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.3390\/molecules27123777","article-title":"68Ga-Labeled [Leu13\u03c8Thz14]Bombesin(7\u201314) derivatives: promising GRPR-targeting PET tracers with low pancreas uptake","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600471X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600471X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:57:05Z","timestamp":1794563825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600471X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":82,"alternative-id":["S022352342600471X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119026","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of PSMA-GRPr heterobivalent radiolabeled conjugates for the diagnosis and therapy of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119026"}}